S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:CYTK

Cytokinetics Stock Forecast, Price & News

$19.68
+1.11 (+5.98 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.00
Now: $19.68
$20.02
50-Day Range
$18.73
MA: $20.77
$23.75
52-Week Range
$8.00
Now: $19.68
$30.14
Volume1.91 million shs
Average Volume887,021 shs
Market Capitalization$1.40 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.45
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274, a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; and AMG 594, a novel cardiac troponin activator that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.
Cytokinetics logo

Headlines

Form 8-K CYTOKINETICS INC For: Feb 25 - StreetInsider.com
February 25, 2021 |  streetinsider.com
Cytokinetics Reports Fourth Quarter 2020 Financial Results
February 25, 2021 |  finance.yahoo.com
Cytokinetics Names Muna Bhanji to Board of Directors
February 18, 2021 |  finance.yahoo.com
Is Duke Energy Stock a Buy? - Nasdaq
February 2, 2021 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYTK
CUSIPN/A
Phone650-624-3000
Employees156
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.87 million
Book Value($0.19) per share

Profitability

Net Income$-121,690,000.00
Net Margins-209.88%

Miscellaneous

Market Cap$1.40 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.72 out of 5 stars

Medical Sector

223rd out of 1,972 stocks

Pharmaceutical Preparations Industry

101st out of 772 stocks

Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$19.68
+1.11 (+5.98 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

Is Cytokinetics a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cytokinetics stock.
View analyst ratings for Cytokinetics
or view top-rated stocks.

What stocks does MarketBeat like better than Cytokinetics?

Wall Street analysts have given Cytokinetics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cytokinetics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Cytokinetics' next earnings date?

Cytokinetics is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Cytokinetics
.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) released its quarterly earnings data on Thursday, February, 25th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.48) by $0.14. Cytokinetics had a negative net margin of 209.88% and a negative trailing twelve-month return on equity of 3,065.14%.
View Cytokinetics' earnings history
.

How has Cytokinetics' stock been impacted by Coronavirus?

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CYTK stock has increased by 63.6% and is now trading at $19.68.
View which stocks have been most impacted by COVID-19
.

What guidance has Cytokinetics issued on next quarter's earnings?

Cytokinetics updated its FY 2021 After-Hours earnings guidance on Thursday, February, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $23-28 million, compared to the consensus revenue estimate of $31.36 million.

What price target have analysts set for CYTK?

10 analysts have issued 1-year price objectives for Cytokinetics' stock. Their forecasts range from $16.00 to $48.00. On average, they expect Cytokinetics' stock price to reach $32.00 in the next year. This suggests a possible upside of 62.6% from the stock's current price.
View analysts' price targets for Cytokinetics
or view top-rated stocks among Wall Street analysts.

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the following people:
  • Mr. Robert I. Blum, CEO, Pres & Director (Age 57, Pay $905.58k)
  • Mr. Ching W. Jaw, Sr. VP & CFO (Age 58, Pay $549.19k)
  • Mr. David W. Cragg, Chief HR & Admin. Officer (Age 65, Pay $480.61k)
  • Mr. Mark A. Schlossberg, Sr. VP of Legal, Gen. Counsel & Sec. (Age 60, Pay $564.47k)
  • Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 57, Pay $652.43k)
  • Dr. James A. Spudich, Co-Founder & Member of Scientific Advisory Board (Age 79)
  • Mr. Robert Wong, VP & Chief Accounting Officer (Age 54)
  • Ms. Diane Weiser, Sr. VP of Corp. Communications & Investor Relations
  • Ms. Bonnie A. Charpentier, Sr. VP of Regulatory Affairs & Compliance (Age 69)
  • Dr. Andrew A. Wolff, Sr. VP and Sr. Fellow, Clinical R&D (Age 66)

What is Robert I. Blum's approval rating as Cytokinetics' CEO?

16 employees have rated Cytokinetics CEO Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among Cytokinetics' employees.

Who are some of Cytokinetics' key competitors?

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (16.40%), PFM Health Sciences LP (1.37%), Northern Trust Corp (1.18%), Bank of New York Mellon Corp (0.97%), Opaleye Management Inc. (0.82%) and Peregrine Capital Management LLC (0.79%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Ching Jaw, Fady Ibraham Malik, John T Henderson, L Patrick Gage, Mark A Schlossberg, Robert I Blum, Sandford D Smith, Santo J Costa, Value Fund L P Biotechnology and Wendall Wierenga.
View institutional ownership trends for Cytokinetics
.

Which institutional investors are selling Cytokinetics stock?

CYTK stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, JPMorgan Chase & Co., Nuveen Asset Management LLC, ClariVest Asset Management LLC, Northern Trust Corp, Russell Investments Group Ltd., Pinnacle Associates Ltd., and Bank of New York Mellon Corp. Company insiders that have sold Cytokinetics company stock in the last year include Bvf Partners L P/Il, Ching Jaw, Fady Ibraham Malik, John T Henderson, L Patrick Gage, Mark A Schlossberg, Robert I Blum, Sandford D Smith, Santo J Costa, and Wendall Wierenga.
View insider buying and selling activity for Cytokinetics
or view top insider-selling stocks.

Which institutional investors are buying Cytokinetics stock?

CYTK stock was bought by a variety of institutional investors in the last quarter, including PFM Health Sciences LP, BlackRock Inc., Peregrine Capital Management LLC, Artal Group S.A., Opaleye Management Inc., CM Management LLC, Candriam Luxembourg S.C.A., and Hillhouse Capital Advisors LTD.. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology.
View insider buying and selling activity for Cytokinetics
or or view top insider-buying stocks.

How do I buy shares of Cytokinetics?

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $19.68.

How much money does Cytokinetics make?

Cytokinetics has a market capitalization of $1.40 billion and generates $26.87 million in revenue each year. The biopharmaceutical company earns $-121,690,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis.

How many employees does Cytokinetics have?

Cytokinetics employs 156 workers across the globe.

What is Cytokinetics' official website?

The official website for Cytokinetics is www.cytokinetics.com.

Where are Cytokinetics' headquarters?

Cytokinetics is headquartered at 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.